drugset / Trial / NCT06638307

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

NCT06638307

Phase 1 Recruiting 240 enrolled Stemline Therapeutics, Inc.
RandomizedSequentialOpen-labelTreatment

Summary

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Timeline

Start
2024-10-25
Primary completion
2027-10-24
Completion
2029-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Elacestrant Other / unclassified Oral
Subject MEN2312 Unknown Oral